Search

Your search keyword '"Loebermann M"' showing total 33 results
Start Over Author "Loebermann M" Search Limiters Available in Library Collection
33 results on '"Loebermann M"'

1. Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients

Author

Antoni, C., Teufel, A., Vogelmann, R., Ebert, M., Balavoine, J., Giostra, E., Berning, M., Hampe, J., Boettler, T., Neumann-Haefelin, C., Thimme, R., De Gottardi, A., Rauch, A., Semmo, N., Ellenrieder, V., Gress, M., Herrmann, A., Stallmach, A., Hoffmann, D., Protzer, U., Kodal, A., Löbermann, M., Götze, T., Keitel-Anselmino, V., Lange, C.M., Zachoval, R., Mayerle, J., Maieron, A., Michl, P., Merle, U., Moradpour, D., Chave, J.-P., Muche, M., Epple, H.-J., Müller-Schilling, M., Kocheise, F., Müller, T., Tacke, F., Roeb, E., Rissland, J., Krawczyk, M., Schulze, P., Semela, D., Spengler, U., Rockstroh, J., Strassburg, C.P., Siebler, J., Schulze zur Wiesch, J., Piecha, F., von Felden, J., Jordan, S., Lohse, A., Sprinzl, M., Galle, P., Stauber, R., Strey, B., Steckstor, W., Schmiegel, W., Brockmeyer, N.H., Canbay, A., Trautwein, C., Uschner, F., Trebicka, J., Weber, T., Wedemeyer, H., Cornberg, M., Manns, M., Wietzke-Braun, P., Günther, R., Willuweit, K., Hilgard, G., Schmidt, H., Zizer, E., Backhus, J., Seufferlein, T., Al-Taie, O., Angeli, W., Beckebaum, S., Erhardt, A., Garrido-Lüneburg, A., Gattringer, H., Genné, D., Gschwantler, M., Gundling, F., Hametner, S., Schöfl, R., Haag, S., Heinzow, H., Heyer, T., Hirschi, C., Jussios, A., Kanzler, S., Kordecki, N., Kraus, M., Kullig, U., Wollschläger, S., Magenta, L., Beretta-Piccoli, B. Terziroli, Menges, M., Mohr, L., Muehlenberg, K., Niederau, C., Paulweber, B., Petrides, A., Pinkernell, M., Piso, R., Rambach, W., Reinhardt, L., Reiser, M., Riecken, B., Rieke, A., Roth, J., Schelling, M., Schlee, P., Schneider, A., Scholz, D., Schott, E., Schuchmann, M., Schulten-Baumer, U., Seelhoff, A., Stich, A., Stickel, F., Ungemach, J., Walter, E., Weber, A., Wege, H., Winzer, T., Abels, W., Adler, M., Audebert, F., Baermann, C., Bästlein, E., Barth, R., Barthel, K., Becker, W., Behrends, J., Benninger, J., Berger, F., Berzow, D., Beyer, T., Bierbaum, M., Blaukat, O., Bodtländer, A., Böhm, G., Börner, N., Bohr, U., Bokemeyer, B., Bruch, H.R., Bucholz, D., Buggisch, P., Matschenz, K., Petersen, J., Burkhard, O., Busch, N., Chirca, C., Delker, R., Diedrich, J., Frank, M., Diehl, M., Tal, A.O., Schneider, M., Dienethal, A., Dietel, P., Dikopoulos, N., Dreck, M., Dreher, F., Drude, L., Ende, K., Ehrle, U., Baumgartl, K., Emke, F., Glosemeyer, R., Felten, G., Hüppe, D., Fischer, J., Fischer, U., Frederking, D., Frick, B., Friese, G., Gantke, B., Geyer, P., Schwind, H.R., Glas, M., Glaunsinger, T., Goebel, F., Göbel, U., Görlitz, B., Graf, R., Gruber, H., Hartmann, C., Klag, C., Härter, G., Herder, M., Heuchel, T., Heuer, S., Hinrichsen, H., Seegers, B., Höffl, K.-H., Hörster, H., Sonne, J.-U., Hofmann, W.P., Holst, F., Hunstiger, M., Hurst, A., Jägel-Guedes, E., John, C., Jung, M., Kallinowski, B., Kapzan, B., Kerzel, W., Khaykin, P., Klarhof, M., Klüppelberg, U., Wolfratshausen, Klugewitz, K., Knapp, B., Knevels, U., Kochsiek, T., Körfer, A., Köster, A., Kuhn, M., Langekamp, A., Künzig, B., Link, R., Littman, M., Löhr, H., Lutz, T., Gute, P., Knecht, G., Lutz, U., Mainz, D., Mahle, I., Maurer, P., Mauss, S., Mayer, C., Möller, H., Heyne, R., Moritzen, D., Mroß, M., Mundlos, M., Naumann, U., Nehls, O., K, Ningel, R., Oelmann, A., Olejnik, H., Gadow, K., Pascher, E., Philipp, A., Pichler, M., Polzien, F., Raddant, R., Riedel, M., Rietzler, S., Rössle, M., Rufle, W., Rump, A., Schewe, C., Hoffmann, C., Schleehauf, D., Schmidt, W., Schmidt-Heinevetter, G., Fabris, J. Schmidtler-von, Schneider, L., Schober, A., Niehaus-Hahn, S., Schwenzer, J., Seidel, T., Seitel, G., Sick, C., Simon, K., Stähler, D., Stenschke, F., Steffens, H., Stein, K., Steinmüller, M., Sternfeld, T., Svensson, K., Tacke, W., Teuber, G., Teubner, K., Thieringer, J., Tomesch, A., Trappe, U., Ullrich, J., Urban, G., Usadel, S., von Lucadou, A., Weinberger, F., Werheid-Dobers, M., Werner, P., Winter, T., Zehnter, E., Zipf, A., Dietz, Julia, Graf, Christiana, Berg, Christoph P., Port, Kerstin, Deterding, Katja, Buggisch, Peter, Peiffer, Kai-Henrik, Vermehren, Johannes, Dultz, Georg, Geier, Andreas, Reiter, Florian P., Bruns, Tony, Schattenberg, Jörn M., Durmashkina, Elena, Gustot, Thierry, Moreno, Christophe, Trauth, Janina, Discher, Thomas, Fischer, Janett, Berg, Thomas, Kremer, Andreas E., Müllhaupt, Beat, Zeuzem, Stefan, and Sarrazin, Christoph

Published
2024
Full Text
View/download PDF

2. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1–3 Infections

Author

Balavoine, J., Giostra, E., Berning, M., Hampe, J., De Gottardi, A., Rauch, A., Semmo, N., Discher, T., Trauth, J., Fischer, J., Gress, M., Günther, R., Heinzow, H., Schmidt, J., Herrmann, A., Stallmach, A., Hilgard, G., Deterding, K., Lange, C.M., Ciesek, S., Wedemeyer, H., Hoffmann, D., Klinker, H., Schulze, P., Kocheise, F., Müller-Schilling, M., Kodal, A., Kremer, A., Ganslmayer, M., Siebler, J., Lammert, F., Rissland, J., Löbermann, M., Götze, T., Canbay, A., Lohse, A., von Felden, J., Jordan, S., Maieron, A., Moradpour, D., Chave, J.-P., Moreno, C., Müller, T., Muche, M., Epple, H.-J., Port, K., von Hahn, T., Cornberg, M., Manns, M., Reinhardt, L., Ellenrieder, V., Rockstroh, J., Schattenberg, J., Sprinzl, M., Galle, P., Roeb, E., Steckstor, M., Schmiegel, W., Brockmeyer, N.H., Seufferlein, T., Stremmel, W., Strey, B., Thimme, R., Teufel, A., Vogelmann, R., Ebert, M., Tomasiewicz, K., Trautwein, C., Tacke, F., Koenen, T., Weber, T., Zachoval, R., Mayerle, J., Raziorrouh, B., Angeli, W., Beckebaum, S., Doberauer, C., Durmashkina, E., Hackelsberger, A., Erhardt, A., Garrido-Lüneburg, A., Gattringer, H., Genné, D., Gschwantler, M., Gundling, F., Hametner, S., Schöfl, R., Hartmann, C., Heyer, T., Hirschi, C., Jussios, A., Kanzler, S., Kordecki, N., Kraus, M., Kullig, U., Wollschläger, S., Magenta, L., Beretta-Piccoli, B. Terziroli, Menges, M., Mohr, L., Muehlenberg, K., Niederau, C., Paulweber, B., Petrides, A., Pinkernell, M., Piso, R., Rambach, W., Reiser, M., Riecken, B., Rieke, A., Roth, J., Schelling, M., Schlee, P., Schneider, A., Scholz, D., Schott, E., Schuchmann, M., Schulten-Baumer, U., Seelhoff, A., Stich, A., Stickel, F., Ungemach, J., Walter, E., Weber, A., Winzer, T., Abels, W., Adler, M., Audebert, F., Baermann, C., Bästlein, E., Barth, R., Barthel, K., Becker, W., Behrends, J., Benninger, J., Berger, F., Berzow, D., Beyer, T., Bierbaum, M., Blaukat, O., Bodtländer, A., Böhm, G., Börner, N., Bohr, U., Bokemeyer, B., Bruch, H.R., Bucholz, D., Burkhard, O., Busch, N., Chirca, C., Delker, R., Diedrich, J., Frank, M., Diehl, M., Dienethal, A., Dietel, P., Dikopoulos, N., Dreck, M., Dreher, F., Drude, L., Ende, K., Ehrle, U., Baumgartl, K., Emke, F., Glosemeyer, R., Felten, G., Hüppe, D., Fischer, U., Frederking, D., Frick, B., Friese, G., Gantke, B., Geyer, P., Schwind, H.R., Glas, M., Glaunsinger, T., Goebel, F., Göbel, U., Görlitz, B., Graf, R., Gruber, H., Härter, G., Herder, M., Heuchel, T., Heuer, S., Höffl, K.-H., Hörster, H., Sonne, J.-U., Hofmann, W.P., Holst, F., Hunstiger, M., Hurst, A., Jägel-Guedes, E., John, C., Jung, M., Kallinowski, B., Kapzan, B., Kerzel, W., Khaykin, P., Klarhof, M., Klüppelberg, U., Klugewitz, K., Knapp, B., Knevels, U., Kochsiek, T., Körfer, A., Köster, A., Kuhn, M., Langekamp, A., Künzig, B., Link, R., Littman, M., Löhr, H., Lutz, T., Knecht, G., Lutz, U., Mainz, D., Mahle, I., Maurer, P., Mayer, C., Meister, V., Möller, H., Heyne, R., Moritzen, D., Mroß, M., Mundlos, M., Naumann, U., Nehls, O., Ningel, K.&R., Oelmann, A., Olejnik, H., Gadow, K., Pascher, E., Petersen, J., Philipp, A., Pichler, M., Polzien, F., Raddant, R., Riedel, M., Rietzler, S., Rössle, M., Rufle, W., Rump, A., Schewe, C., Hoffmann, C., Schleehauf, D., Schmidt, K.J., Schmidt, W., Schmidt-Heinevetter, G., Schmidtler-von Fabris, J., Schnaitmann, E., Schneider, L., Schober, A., Niehaus-Hahn, S., Schwenzer, J., Seidel, T., Seitel, G., Sick, C., Simon, K.G., Stähler, D., Stenschke, F., Steffens, H., Stein, K., Steinmüller, M., Sternfeld, T., Svensson, K., Tacke, W., Teuber, G., Teubner, K., Thieringer, J., Tomesch, A., Trappe, U., Ullrich, J., Urban, G., Usadel, S., von Lucadou, A., Weinberger, F., Werheid-Dobers, M., Werner, P., Winter, T., Zehnter, E., Zipf, A., Dietz, Julia, Spengler, Ulrich, Müllhaupt, Beat, Schulze zur Wiesch, Julian, Piecha, Felix, Mauss, Stefan, Seegers, Barbara, Hinrichsen, Holger, Antoni, Christoph, Wietzke-Braun, Perdita, Peiffer, Kai-Henrik, Berger, Annemarie, Matschenz, Katrin, Buggisch, Peter, Backhus, Johanna, Zizer, Eugen, Boettler, Tobias, Neumann-Haefelin, Christoph, Semela, David, Stauber, Rudolf, Berg, Thomas, Berg, Christoph, Zeuzem, Stefan, Vermehren, Johannes, and Sarrazin, Christoph

Published
2021
Full Text
View/download PDF

3. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals

Author

Antoni, C., Vogelmann, R., Ebert, M., Backhus, J., Seufferlein, T., Balavoine, J., Giostra, E., Berg, C., Cornberg, M., Wedemeyer, H., Manns, M., De Gottardi, A., Esteban, R., Discher, T., Roeb, E., Gress, M., Günther, R., Wietzke-Braun, P., Herrmann, A., Stallmach, A., Hoffmann, D., Klinker, H., Kodal, A., Lammert, F., Löbermann, M., Schulze zur Wiesch, J., von Felden, J., Piecha, F., Lohse, A., Götze, T., Malfertheiner, P., Mayerle, J., Moradpour, D., Moreno, C., Neumann-Haefelin, C., Thimme, R., Reinhardt, L., Ellenrieder, V., Schattenberg, J., Sprinzl, M., Galle, P., Schmidt, J., Schott, E., Epple, H.-J., Siebler, J., Stauber, R., Steckstor, M., Schmiegel, W., Stremmel, W., Strey, B., Tomasiewicz, K., Trautwein, C., Zachoval, R., Angeli, W., Beckebaum, S., Doberauer, C., Ende, K., Erhardt, A., Garrido-Lüneburg, A., Gattringer, H., Genné, D., Gschwantler, M., Gundling, F., Hartmann, C., Heyer, T., Hirschi, C., Kanzler, S., Kordecki, N., Kraus, M., Kullig, U., Magenta, L., Terziroli Beretta-Piccoli, B., Menges, M., Mohr, L., Muehlenberg, K., Niederau, C., Paulweber, B., Petrides, A., Piso, R., Rambach, W., Reiser, M., Riecken, B., Roth, J., Schöfl, R., Maieron, A., Schneider, A., Schuchmann, M., Schulten-Baumer, U., Seelhoff, A., Semela, D., Stich, A., Vollmer, C., Brückner, J., Ungemach, J., Walter, E., Weber, A., Winzer, T., Abels, W., Adler, M., Audebert, F., Baermann, C., Bästlein, E., Barth, R., Barthel, K., Baumgartl, K., Becker, W., Benninger, J., Beyer, T., Bodtländer, A., Böhm, G., Bohr, U., Moll, A., Naumann, U., Börner, N., Bruch, H.R., Busch, N., Burkhard, O., Chirca, C., Dienethal, A., Dietel, P., Dreher, F., Efken, P., Ehrle, U., Emke, F., Fischer, J., Fischer, U., Frederking, D., Frick, B., Gantke B, B., Geyer, P., Glaunsinger, T., Goebel, F., Göbel, U., Graf, R., Herder, M., Heuchel, T., Heuer, S., Heyne, R., Höffl, K.H., Hofmann, W.P., Holst, F., Hörster, H., John, C., Jung, M.C., Kallinowski, B., Kerzel, W., Khaykin, P., Klarhof, M., Knapp, B., Knevels, U., Körfer, A., Köster, A., Künzig, B., Langenkamp, A., Kuhn, M., Littman, M., Löhr, H., Ludwig, L., Lutz, U., Maurer, P., Mayer, C., Meister, V., Moritzen, D., Mroß, M., Mundlos, M., Nehls, O., Ningel, K., Oelmann, A., Olejnik, H., Pascher, E., Philipp, A., Pichler, M., Polzien, F., Raddant, R., Riedel, M., Rietzler, S., Rump, A., Schmidt, W., Schmidtler-von Fabris, J., Schneider, L., Schober, A., Schwenzer, J., Seidel, T., Seitel, G., Sick, C., Simon, K., Stähler, D., Steffens, H., Svensson, K., Tacke, W., Teubner, K., Thieringer, J., Trappe, U., Ullrich, J., Usadel, S., von Lucadou, A., Werheid-Dobers, M., Zehnter, E., Zipf, A., Dietz, Julia, Susser, Simone, Vermehren, Johannes, Peiffer, Kai-Henrik, Grammatikos, Georgios, Berger, Annemarie, Ferenci, Peter, Buti, Maria, Müllhaupt, Beat, Hunyady, Bela, Hinrichsen, Holger, Mauss, Stefan, Petersen, Jörg, Buggisch, Peter, Felten, Gisela, Hüppe, Dietrich, Knecht, Gaby, Lutz, Thomas, Schott, Eckart, Berg, Christoph, Spengler, Ulrich, von Hahn, Thomas, Berg, Thomas, Zeuzem, Stefan, and Sarrazin, Christoph

Published
2018
Full Text
View/download PDF

6. Long-term safety and efficacy of Eculizumab in Aquaporin-4 IgG-positive NMOSD

Author

Wingerchuk, D.M., Fujihara, K., Palace, J., Berthele, A., Levy, M., Kim, H.J., Nakashima, I., Oreja-Guevara, C., Wang, K.-C., Miller, L., Shang, S., Sabatella, G., Yountz, M., Pittock, S.J., Villa, A., Garcea, O., Manin, A., Melamud, L., Aguirre, F., Fernandez, V., Munoz, D.J., Amor, J., Bocchiardo, C., Obregon, C.D.D., Laffue, A., Paez, M.F., Perez, R.M., Rocchi, V., Teijeiro, L., De Virgiliis, M., Cordoba, M., Ingolotti, M., Lupinacci, A., Ballario, C., Chiesa, A., Gomez, H., Mainella, C., Lattini, H., Barnett, M., Barton, J., Beadnall, H., Garber, J., Hardy, T., Pollard, J., Trewin, B., Shuey, N., Bryson, A., French, A., Laing, J., Law, L.Y., Plummer, C., Sanders, L., Sedal, L., Winkel, A., Neal, A., Habek, M., Adamec, I., Barun, B., Crnosija, L., Gabelic, T., Pitha, J., Nytrova, P., Novakova, I., Tyblova, M., Krasulova, E., Pavlickova, J., Petersen, T., Rasmussen, P., Stilund, M., Svendsen, K., Diem, R., Platten, M., Berberich, A., Jaschonek, H., Wildemann, B., Biberacher, V.M., Brinkhoff, K., Golkowski, D., Kowarik, M., Lehmann-Horn, K., Pongratz, V., Zettl, U., Klinke, J., Loebermann, M., Meister, S., Rimmele, F., Winkelmann, A., Lau, A.Y.L., Au, L.W.C., Fan, S.Y.F., Ip, V.H.L., Ma, S.H., Ma, K.Y.K., Mok, C.T.V., Patti, F., Messina, S., Proietto, M., Filla, A., Morra, V.B., Costabile, T., Nozzolillo, A., Sacc, Sacca, Tackley, George, and MATUR, ZELİHA

Subjects
0301 basic medicine, medicine.medical_specialty, Neuromyelitis optica, business.industry, Maintenance dose, Eculizumab, Placebo, Interim analysis, medicine.disease, Confidence interval, ddc, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Aquaporin 4, Neurology, Internal medicine, Medicine, Neurology (clinical), Adverse effect, business, Research Articles, 030217 neurology & neurosurgery, Research Article, medicine.drug
Abstract

Objective\udDuring PREVENT (NCT01892345), eculizumab significantly reduced relapse risk versus placebo in patients with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD). We report an interim analysis of PREVENT's ongoing open-label extension (OLE; NCT02003144) evaluating eculizumab's long-term safety and efficacy.\ud\udMethods\udPatients who completed PREVENT could enroll in the OLE to receive eculizumab (maintenance dose = 1,200 mg/2 weeks, after a blinded induction phase). Safety and efficacy data from PREVENT and its OLE (interim data cut, July 31, 2019) were combined for this analysis.\ud\udResults\udAcross PREVENT and the OLE, 137 patients received eculizumab and were monitored for a median (range) of 133.3 weeks (5.1–276.9 weeks), for a combined total of 362.3 patient-years (PY). Treatment-related adverse event (AE) and serious adverse event (SAE) rates were 183.5 in 100 PY and 8.6 in 100 PY, respectively. Serious infection rates were 10.2 in 100 PY in eculizumab-treated patients versus 15.1 in 100 PY in the PREVENT placebo group. No patient developed a meningococcal infection. At 192 weeks (3.7 years), 94.4% (95% confidence interval [CI], 88.6–97.3) of patients remained adjudicated relapse-free. The adjudicated annualized relapse rate was 0.025 (95% CI = 0.013–0.048) in all eculizumab-treated patients versus 0.350 (95% CI = 0.199–0.616) in the PREVENT placebo group. During the OLE, 37% of patients (44 of 119 patients) stopped or decreased background immunosuppressive therapy use.\ud\udInterpretation\udThis analysis demonstrates that eculizumab's long-term safety profile in NMOSD is consistent with its established profile across other indications. This analysis also demonstrated the sustained ability of long-term eculizumab treatment to reduce relapse risk in patients with AQP4-IgG+ NMOSD. ANN NEUROL 2021;89:1088–1098

Published
2021

8. [Fever after travel to tropical regions: Malaria and other emergencies]

Author

Loebermann M, C J Hemmer, and E C Reisinger

Subjects
Gynecology, medicine.medical_specialty, biology, business.industry, Malaria-Schnelltests, Inkubationszeiten, Plasmodium falciparum, Tropical diseases, Rapid diagnostic tests, 030231 tropical medicine, biology.organism_classification, Incubation periods, 03 medical and health sciences, 0302 clinical medicine, Leitthema, Tropenkrankheiten, Emergency Medicine, medicine, Differential diagnosis, 030212 general & internal medicine, business, Differenzialdiagnosen
Abstract

Zusammenfassung Hintergrund Bei Tropenrückkehrern ist Malaria die häufigste Fieberursache. Die häufigste und gleichzeitig gefährlichste Art der Malaria ist die Malaria tropica. Sie wird durch Plasmodium falciparum verursacht. Methode Recherche und Auswertung der aktuellen Literatur. Ergebnisse und Schlussfolgerung Über 90 % der Malariaerkrankungen und der Malariatodesfälle betreffen Afrika. Der Rest verteilt sich auf Indien, Südost-Asien, Ozeanien, und Lateinamerika. In Deutschland wurden in den letzten 10 Jahren laut Robert Koch-Institut (RKI) zwischen 513 und 613 Malariafälle gemeldet, darunter zwischen 389 und 541 Fälle der potenziell tödlichen Malaria tropica (Plasmodium falciparum). Ein Malariaverdacht besteht bei jedem Fieber, das bis zu 4 Monate nach einem Tropenaufenthalt auftritt, bei Einwanderern aus Malariaregionen auch noch Jahre nach dem letzten Tropenaufenthalt. Die sog. Malaria-Schnelltests sind – v. a. im Hinblick auf die durch Plasmodium falciparum hervorgerufene Malaria tropica – inzwischen teilweise brauchbar. Sie ergeben jedoch gelegentlich falsch-negative oder falsch-positive Befunde. Die Therapie der Malaria hängt von der Plasmodien-Art, dem klinischen Schweregrad und der Region, in der die Infektion erworben wurde, und ferner vom Schweregrad der Erkrankung ab.

Published
2020

9. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections

Author

Dietz, Julia, Spengler, Ulrich, Mullhaupt, Beat, zur Wiesch, Julian Schulze, Piecha, Felix, Mauss, Stefan, Seegers, Barbara, Hinrichsen, Holger, Antoni, Christoph, Wietzke-Braun, Perdita, Peiffer, Kai-Henrik, Berger, Annemarie, Matschenz, Katrin, Buggisch, Peter, Backhus, Johanna, Zizer, Eugen, Boettler, Tobias, Neumann-Haefelin, Christoph, Semela, David, Stauber, Rudolf, Berg, Thomas, Berg, Christoph, Zeuzem, Stefan, Vermehren, Johannes, Sarrazin, Christoph, Balavoine, J., Giostra, E., Berning, M., Hampe, J., De Gottardi, A., Rauch, A., Semmo, N., Discher, T., Trauth, J., Fischer, J., Gress, M., Guenther, R., Heinzow, H., Schmidt, J., Herrmann, A., Stallmach, A., Hilgard, G., Deterding, K., Lange, C. M., Ciesek, S., Wedemeyer, H., Hoffmann, D., Klinker, H., Schulze, P., Kocheise, F., Mueller-Schilling, M., Kodal, A., Kremer, A., Ganslmayer, M., Siebler, J., Lammert, F., Rissland, J., Loebermann, M., Goetze, T., Canbay, A., Lohse, A., von Felden, J., Jordan, S., Maieron, A., Moradpour, D., Chave, J. -P., Moreno, C., Mueller, T., Muche, M., Epple, H. -J., Port, K., von Hahn, T., Cornberg, M., Manns, M., Reinhardt, L., Ellenrieder, V., Rockstroh, J., Schattenberg, J., Sprinzl, M., Galle, P., Roeb, E., Steckstor, M., Schmiegel, W., Brockmeyer, N. H., Seufferlein, T., Stremmel, W., Strey, B., Thimme, R., Teufel, A., Vogelmann, R., Ebert, M., Tomasiewicz, K., Trautwein, C., Tacke, F., Koenen, T., Weber, T., Zachoval, R., Mayerle, J., Raziorrouh, B., Angeli, W., Beckebaum, S., Doberauer, C., Durmashkina, E., Hackelsberger, A., Erhardt, A., Garrido-Luneburg, A., Gattringer, H., Genne, D., Gschwantler, M., Gundling, F., Hametner, S., Schofl, R., Hartmann, C., Heyer, T., Hirschi, C., Jussios, A., Kanzler, S., Kordecki, N., Kraus, M., Kullig, U., Wollschlager, S., Magenta, L., Beretta-Piccoli, B. Terziroli, Menges, M., Mohr, L., Muehlenberg, K., Niederau, C., Paulweber, B., Petrides, A., Pinkernell, M., Piso, R., Rambach, W., Reiser, M., Riecken, B., Rieke, A., Roth, J., Schelling, M., Schlee, P., Schneider, A., Scholz, D., Schott, E., Schuchmann, M., Schulten-Baumer, U., Seelhoff, A., Stich, A., Stickel, F., Ungemach, J., Walter, E., Weber, A., Winzer, T., Abels, W., Adler, M., Baermann, C., Bastlein, E., Barth, R., Barthel, K., Becker, W., Behrends, J., Benninger, J., Berger, F., Berzow, D., Beyer, T., Bierbaum, M., Blaukat, O., Bodtlander, A., Bohm, G., Borner, N., Bohr, U., Bokemeyer, B., Bruch, H. R., Bucholz, D., Burkhard, O., Busch, N., Chirca, C., Delker, R., Diedrich, J., Frank, M., Diehl, M., Dienethal, A., Dietel, P., Dikopoulos, N., Dreck, M., Dreher, F., Drude, L., Ende, K., Ehrle, U., Baumgartl, K., Emke, F., Glosemeyer, R., Felten, G., Huppe, D., Fischer, U., Frederking, D., Frick, B., Friese, G., Gantke, B., Geyer, P., Schwind, H. R., Glas, M., Glaunsinger, T., Goebel, F., Gobel, U., Gorlitz, B., Graf, R., Gruber, H., Harter, G., Herder, M., Heuchel, T., Heuer, S., Hoffl, K. -H., Horster, H., Sonne, J. -U., Hofmann, W. P., Holst, F., Hunstiger, M., Hurst, A., Jagel-Guedes, E., John, C., Jung, M., Kallinowski, B., Kapzan, B., Kerzel, W., Khaykin, P., Klarhof, M., Kluppelberg, U., Klugewitz, K., Knapp, B., Knevels, U., Kochsiek, T., Korfer, A., Koster, A., Kuhn, M., Langekamp, A., Kunzig, B., Link, R., Littman, M., Lohr, H., Lutz, T., Knecht, G., Lutz, U., Mainz, D., Mahle, I., Maurer, P., Mayer, C., Meister, V., Moller, H., Heyne, R., Moritzen, D., Mross, M., Mundlos, M., Naumann, U., Nehls, O., Ningel, R., Oelmann, A., Olejnik, H., Gadow, K., Pascher, E., Petersen, J., Philipp, A., Pichler, M., Polzien, F., Raddant, R., Riedel, M., Rietzler, S., Rossle, M., Rufle, W., Rump, A., Schewe, C., Hoffmann, C., Schleehauf, D., Schmidt, K. J., Schmidt, W., Schmidt-Heinevetter, G., Schmidtler-von Fabris, J., Schnaitmann, E., Schneider, L., Schober, A., Niehaus-Hahn, S., Schwenzer, J., Seidel, T., Seitel, G., Sick, C., Simon, K. G., Stahler, D., Stenschke, F., Steffens, H., Stein, K., Steinmuller, M., Sternfeld, T., Svensson, K., Tacke, W., Teuber, G., Teubner, K., Thieringer, J., Tomesch, A., Trappe, U., Ullrich, J., Urban, G., Usadel, S., von Lucadou, A., Weinberger, F., Werheid-Dobers, M., Werner, P., Winter, T., Zehnter, E., Zipf, A., Dietz, Julia, Spengler, Ulrich, Mullhaupt, Beat, zur Wiesch, Julian Schulze, Piecha, Felix, Mauss, Stefan, Seegers, Barbara, Hinrichsen, Holger, Antoni, Christoph, Wietzke-Braun, Perdita, Peiffer, Kai-Henrik, Berger, Annemarie, Matschenz, Katrin, Buggisch, Peter, Backhus, Johanna, Zizer, Eugen, Boettler, Tobias, Neumann-Haefelin, Christoph, Semela, David, Stauber, Rudolf, Berg, Thomas, Berg, Christoph, Zeuzem, Stefan, Vermehren, Johannes, Sarrazin, Christoph, Balavoine, J., Giostra, E., Berning, M., Hampe, J., De Gottardi, A., Rauch, A., Semmo, N., Discher, T., Trauth, J., Fischer, J., Gress, M., Guenther, R., Heinzow, H., Schmidt, J., Herrmann, A., Stallmach, A., Hilgard, G., Deterding, K., Lange, C. M., Ciesek, S., Wedemeyer, H., Hoffmann, D., Klinker, H., Schulze, P., Kocheise, F., Mueller-Schilling, M., Kodal, A., Kremer, A., Ganslmayer, M., Siebler, J., Lammert, F., Rissland, J., Loebermann, M., Goetze, T., Canbay, A., Lohse, A., von Felden, J., Jordan, S., Maieron, A., Moradpour, D., Chave, J. -P., Moreno, C., Mueller, T., Muche, M., Epple, H. -J., Port, K., von Hahn, T., Cornberg, M., Manns, M., Reinhardt, L., Ellenrieder, V., Rockstroh, J., Schattenberg, J., Sprinzl, M., Galle, P., Roeb, E., Steckstor, M., Schmiegel, W., Brockmeyer, N. H., Seufferlein, T., Stremmel, W., Strey, B., Thimme, R., Teufel, A., Vogelmann, R., Ebert, M., Tomasiewicz, K., Trautwein, C., Tacke, F., Koenen, T., Weber, T., Zachoval, R., Mayerle, J., Raziorrouh, B., Angeli, W., Beckebaum, S., Doberauer, C., Durmashkina, E., Hackelsberger, A., Erhardt, A., Garrido-Luneburg, A., Gattringer, H., Genne, D., Gschwantler, M., Gundling, F., Hametner, S., Schofl, R., Hartmann, C., Heyer, T., Hirschi, C., Jussios, A., Kanzler, S., Kordecki, N., Kraus, M., Kullig, U., Wollschlager, S., Magenta, L., Beretta-Piccoli, B. Terziroli, Menges, M., Mohr, L., Muehlenberg, K., Niederau, C., Paulweber, B., Petrides, A., Pinkernell, M., Piso, R., Rambach, W., Reiser, M., Riecken, B., Rieke, A., Roth, J., Schelling, M., Schlee, P., Schneider, A., Scholz, D., Schott, E., Schuchmann, M., Schulten-Baumer, U., Seelhoff, A., Stich, A., Stickel, F., Ungemach, J., Walter, E., Weber, A., Winzer, T., Abels, W., Adler, M., Baermann, C., Bastlein, E., Barth, R., Barthel, K., Becker, W., Behrends, J., Benninger, J., Berger, F., Berzow, D., Beyer, T., Bierbaum, M., Blaukat, O., Bodtlander, A., Bohm, G., Borner, N., Bohr, U., Bokemeyer, B., Bruch, H. R., Bucholz, D., Burkhard, O., Busch, N., Chirca, C., Delker, R., Diedrich, J., Frank, M., Diehl, M., Dienethal, A., Dietel, P., Dikopoulos, N., Dreck, M., Dreher, F., Drude, L., Ende, K., Ehrle, U., Baumgartl, K., Emke, F., Glosemeyer, R., Felten, G., Huppe, D., Fischer, U., Frederking, D., Frick, B., Friese, G., Gantke, B., Geyer, P., Schwind, H. R., Glas, M., Glaunsinger, T., Goebel, F., Gobel, U., Gorlitz, B., Graf, R., Gruber, H., Harter, G., Herder, M., Heuchel, T., Heuer, S., Hoffl, K. -H., Horster, H., Sonne, J. -U., Hofmann, W. P., Holst, F., Hunstiger, M., Hurst, A., Jagel-Guedes, E., John, C., Jung, M., Kallinowski, B., Kapzan, B., Kerzel, W., Khaykin, P., Klarhof, M., Kluppelberg, U., Klugewitz, K., Knapp, B., Knevels, U., Kochsiek, T., Korfer, A., Koster, A., Kuhn, M., Langekamp, A., Kunzig, B., Link, R., Littman, M., Lohr, H., Lutz, T., Knecht, G., Lutz, U., Mainz, D., Mahle, I., Maurer, P., Mayer, C., Meister, V., Moller, H., Heyne, R., Moritzen, D., Mross, M., Mundlos, M., Naumann, U., Nehls, O., Ningel, R., Oelmann, A., Olejnik, H., Gadow, K., Pascher, E., Petersen, J., Philipp, A., Pichler, M., Polzien, F., Raddant, R., Riedel, M., Rietzler, S., Rossle, M., Rufle, W., Rump, A., Schewe, C., Hoffmann, C., Schleehauf, D., Schmidt, K. J., Schmidt, W., Schmidt-Heinevetter, G., Schmidtler-von Fabris, J., Schnaitmann, E., Schneider, L., Schober, A., Niehaus-Hahn, S., Schwenzer, J., Seidel, T., Seitel, G., Sick, C., Simon, K. G., Stahler, D., Stenschke, F., Steffens, H., Stein, K., Steinmuller, M., Sternfeld, T., Svensson, K., Tacke, W., Teuber, G., Teubner, K., Thieringer, J., Tomesch, A., Trappe, U., Ullrich, J., Urban, G., Usadel, S., von Lucadou, A., Weinberger, F., Werheid-Dobers, M., Werner, P., Winter, T., Zehnter, E., and Zipf, A.

Published
2021

11. Focal Myositis in Salmonella paratyphi B Infection: A Case Report

Author

Geerdes-Fenge H, E C Reisinger, Loebermann M, C J Hemmer, and Kolarov C

Subjects
Salmonella, Pathology, medicine.medical_specialty, biology, business.industry, Focal myositis, Salmonella paratyphi B, biology.organism_classification, medicine.disease_cause, medicine.disease, Medius, Bacterial myositis, Medicine, Iliopsoas, business, Myositis
Abstract

Background: We report a case of focal myositis caused by an infection with Salmonella paratyphi B in an 18-year-old immuno-competent woman. Methods: Case report and review of the literature on Salmonella causing (pyo)-myositis. Results: An 18-year-old woman developed a focal myositis of the iliopsoas, gluteus medius and piriformis muscles on the right side occurring 2 days after onset of fever caused by Salmonella paratyphi B infection. Other reasons for focal myositis were excluded. Conclusion: This is the first reported case of focal myositis being caused by an infection with Salmonella paratyphi B in a previously healthy patient.

Published
2019
Full Text
View/download PDF

12. Host defense versus immunosuppression: Male and female Schistosoma mansoni differentially impact the host’s immune system

Author

Sombetzki, M, Koslowski, N, Rabes, A, Seneberg, S, Winkelmann, F, Fritzsche, C, Loebermann, M, and Reisinger, EC

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Schistosomiasis remains a major cause of morbidity and mortality, and in the tropics and subtropics, in particular, infection rates are high [ref:1]. The efficacy of anthelmintic therapy is limited since it has no effect on immature parasite stages and does not prevent re-infection. The root[for full text, please go to the a.m. URL], Infektiologie Update 2018; 26. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG)

Published
2018
Full Text
View/download PDF

13. 24-nor-ursodeoxycholic acid impairs inflammatory response and hepatic fibrosis in a murine model of Schistosoma mansoni infection

Author

Sombetzki, M, Loebermann, M, Fickert, P, Fuchsbichler, A, Langner, C, Gumhold, J, Silbert, D, Riebold, D, Holtfreter, MC, Nizze, H, Trauner, M, and Reisinger, EC

Subjects
ddc: 610, parasitic diseases, 610 Medical sciences, Medicine
Abstract

Objectives: Vigorous intrahepatic granuloma formation and fibrosis in response to parasite eggs specify the pathological picture of Schistosoma mansoni infection as one of the worldwide leading causes for liver fibrosis and portal hypertension. Following our previous observations that 24-nor-ursodeoxycholic[for full text, please go to the a.m. URL], 10. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010)

Published
2010
Full Text
View/download PDF

16. Influenza in Adults Seeking Care at Seven European Emergency Departments: A Prospective Active Surveillance During the 2019-2020 Influenza Season.

Author

Amour S, Rubio AP, Orsi A, Oppert M, Loebermann M, Del Pozo Vegas C, Tazarourte K, Douplat M, Jacquin L, Icardi G, Walker J, Glass A, Nealon J, Chaves SS, Bricout H, and Vanhems P

Subjects
Humans, Female, Male, Middle Aged, Adult, Aged, Prospective Studies, Europe epidemiology, Young Adult, Adolescent, Aged, 80 and over, Patient Acceptance of Health Care statistics & numerical data, Influenza, Human epidemiology, Influenza, Human diagnosis, Emergency Service, Hospital statistics & numerical data, Seasons
Abstract

Background: Influenza can be associated with nonrespiratory disease presentation, but these are less well documented due to the lack of routine testing for influenza in the healthcare system, especially if patients do not present with influenza-like illness (ILI). We aimed to measure the proportion of influenza cases seeking care at emergency department (ED) for a nontraumatic cause, to describe their clinical presentation and their ED-discharge diagnosis., Methods: The study was conducted at seven hospitals in France, Spain, Italy and Germany during the 2019-20 influenza season, for a period of 10 weeks. Patients (≥ 18 years) consulting for nontraumatic causes at the ED were invited to participate. Consenting patients provided upper respiratory swab samples for influenza testing by reverse transcription polymerase chain reaction. Clinical and demographic data were collected., Results: There were 8678 patients included, 50.7% were female and the median age was 57 years. Among them, 494 (5.7%) were laboratory-confirmed influenza (LCI) cases. Nonetheless, only 24.3% of LCI cases had an ED-discharge of influenza. Of all cases confirmed as influenza, 47.6% had a nonrespiratory discharge diagnosis, which frequency increased with age. ILI case definition from the European Centre for Disease Prevention and Control was the most frequently met among influenza cases (68.6%). Older patients (≥ 65 years) were less frequently identified based on any ILI signs/symptoms., Conclusion: Our findings indicate that the impact of influenza among patients seeking care at the ED cannot be easily assessed based on clinical presentation and medical records alone. Preventing influenza among adult population may reduce healthcare utilization., (© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

17. Performance Analysis of Serodiagnostic Tests to Characterize the Incline and Decline of the Individual Humoral Immune Response in COVID-19 Patients: Impact on Diagnostic Management.

Author

von Possel R, Menge B, Deschermeier C, Fritzsche C, Hemmer C, Geerdes-Fenge H, Loebermann M, Schulz A, Lattwein E, Steinhagen K, Tönnies R, Ahrendt R, and Emmerich P

Subjects
Humans, Immunity, Humoral, SARS-CoV-2, Serologic Tests, Immunoglobulin G, COVID-19 Testing, COVID-19 diagnosis
Abstract

Serodiagnostic tests for antibody detection to estimate the immunoprotective status regarding SARS-CoV-2 support diagnostic management. This study aimed to investigate the performance of serological assays for COVID-19 and elaborate on test-specific characteristics. Sequential samples ( n = 636) of four panels (acute COVID-19, convalescent COVID-19 (partly vaccinated post-infection), pre-pandemic, and cross-reactive) were tested for IgG by indirect immunofluorescence test (IIFT) and EUROIMMUN EUROLINE Anti-SARS-CoV-2 Profile (IgG). Neutralizing antibodies were determined by a virus neutralization test (VNT) and two surrogate neutralization tests (sVNT, GenScript cPass, and EUROIMMUN SARS-CoV-2 NeutraLISA). Analysis of the acute and convalescent panels revealed high positive (78.3% and 91.6%) and negative (91.6%) agreement between IIFT and Profile IgG. The sVNTs revealed differences in their positive (cPass: 89.4% and 97.0%, NeutraLISA: 71.5% and 72.1%) and negative agreement with VNT (cPass: 92.3% and 50.0%, NeutraLISA: 95.1% and 92.5%) at a diagnostic specificity of 100% for all tests. The cPass showed higher inhibition rates than NeutraLISA at VNT titers below 1:640. Cross-reactivities were only found by cPass (57.1%). Serodiagnostic tests, which showed substantial agreement and fast runtime, could provide alternatives for cell-based assays. The findings of this study suggest that careful interpretation of serodiagnostic results obtained at different times after SARS-CoV-2 antigen exposure is crucial to support decision-making in diagnostic management.

Published
2024
Full Text
View/download PDF

18. Side effects following vaccination in multiple sclerosis: a prospective, multi-centre cohort study.

Author

Winkelmann A, Metze C, Zettl UK, and Loebermann M

Subjects
Female, Humans, Male, Prospective Studies, Tetanus Toxoid, Vaccination adverse effects, Drug-Related Side Effects and Adverse Reactions, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Abstract

Vaccines play a crucial role in preventing infections in patients with multiple sclerosis (MS), although concerns have been raised about potential worsening of the underlying disease. To investigate this, we conducted a prospective, multicentre, non-randomized observational study assessing changes in disease activity, safety, and clinical tolerability of vaccination in 222 MS patients on disease-modifying drugs. The majority of patients were female (76.6%) and 89.6% had relapsing-remitting MS. The vaccines administered were primarily seasonal influenza (56.3%) or tetanus-based vaccines (33.8%). Disease activity, as measured by annualized relapse rate, decreased significantly from 0.64 the year prior to vaccination to 0.38 in the following year. Moreover, the extended disability status scale remained stable within six months after vaccination in comparison to pre-vaccination values. Side effects were reported in 19.2% of vaccinated subjects, most commonly local side effects (65.2%) or flu-like symptoms (34.8%). Our findings suggest that standard non-live vaccines are safe and well-tolerated in MS patients and do not negatively impact disease activity., (© 2023. Springer Nature Limited.)

Published
2023
Full Text
View/download PDF

19. SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study.

Author

Frahm N, Fneish F, Ellenberger D, Haas J, Loebermann M, Parciak T, Peters M, Pöhlau D, Rodgers J, Röper AL, Schilling S, Stahmann A, Temmes H, Zettl UK, and Middleton RM

Abstract

Background: Vaccines offer people with multiple sclerosis (PwMS) an effective protection against severe COVID-19 disease courses. However, representative real-world data on the tolerability of SARS-CoV-2 vaccines in PwMS are limited. We aimed at analysing vaccination reactions (VRs) and MS deterioration following SARS-CoV-2 vaccinations in German and United Kingdom (UK) PwMS, especially regarding gender-specific differences., Methods: The German Multiple Sclerosis Society and the UK MS Registry acquired health data via an online system following the first (X 1 ) and second SARS-CoV-2 vaccination (X 2 ), respectively: sociodemographic and clinical data, vaccines used, VRs, MS deterioration (worsened or new MS symptoms, Germany only) and relapses (Germany only). The frequencies of VRs and MS deterioration were analysed stratified by gender., Findings: Following X 1 (X 2 ), 2346 (1835) German PwMS and 3796 (683) UK PwMS participated in the study. The most frequent vaccination scheme was two-dose tozinameran for Germany (77·1%, 1424/1847) and two-dose AZD1222 for the UK (61·3%, 419/683). The most common VRs were fatigue, headache and pain (at the injection site) and occurred more often in women compared with men. German PwMS reported VRs more frequently after X 2 vs. X 1 (65·4% [1201/1835] vs. 61·2% [1435/2346]), while for UK patients it was the opposite (X 1 vs. X 2 : 48·7% [1849/3796] vs. 30·0% [205/683]). MS deterioration occurred in 19·0% (445/2346) of the German PwMS without resulting in gender-specific differences. Fatigue and gait impairment were the most frequent deteriorated MS symptoms., Interpretation: Female PwMS reported experiencing VRs more often than men. Longitudinal data are needed to enable valid statements regarding long-term MS deterioration and long-lasting VRs., Funding: German Multiple Sclerosis Society (DMSG Bundesverband e.V.), Biogen, Bristol Myers Squibb, Merck Serono, Mylan, Novartis, Roche and Sanofi., Competing Interests: Niklas Frahm is an employee of the MSFP. Moreover, he is an employee of Rostock's University Medical Center and received travel funds for research meetings from Novartis; none resulted in a conflict of interest. Firas Fneish, Melanie Peters, David Ellenberger and Sarah Schilling had no personal financial interests to disclose other than being employees of the German MS Registry; none resulted in a conflict of interest. Tina Parciak had no personal financial interests to disclose. Anna-Lena Röper is employee of the MSFP and Germany MS society, which is funded by many public and corporate sponsors. She received travel funds from Novartis. None resulted in a conflict of interest. Micha Löbermann received speaker honoraria from Sanofi, AbbVie and Pfizer, he served as investigator in vaccine studies sponsored by Janssen, GSK and Novartis; none resulted in a conflict of interest. Herbert Temmes has no personal pecuniary interests to disclose, other than being the Secretary General of the German MS Society, federal association, which receives funding from a range of public and corporate sponsors, recently including Bundesgesundheitsministerium (BMG), The German Innovation Fund (G-BA), The German MS Trust, Biogen, Bristol Myers Squibb, Merck Serono, Novartis, Roche, Sanofi, Viatris (former Mylan); none resulted in a conflict of interest. Judith Haas has no personal pecuniary interests to disclose, other than being the President of the German MS Society, federal association, which receives funding from a range of public and corporate sponsors, recently including BMG, G-BA, The German MS Trust, Biogen, Bristol Myers Squibb, Merck Serono, Novartis, Roche, Sanofi, Viatris (former Mylan); none resulted in a conflict of interest. Dieter Pöhlau received speaking fees, travel support and financial support for research projects from: Allmirall, Bayer, Biogen-Idec, Merck-Serono, Octapharm, Novartis, Roche, Sanofi-Aventis and Teva; none resulted in a conflict of interest. Jeff Rodgers has no personal pecuniary interests to disclose, other than being an employee of the UK MS Register which is funded by the MS Society, travel research and conference costs are also funded by them; none resulted in a conflict of interest. Uwe K. Zettl has received speaking fees, travel support and /or financial support for research activities from Alexion, Almirall, Bayer, Biogen, Bristol-Myers-Squibb, Janssen, Merck Serono, Novartis, Octapharm, Roche, Sanofi Genzyme, Teva as well as EU, BMBF, BMWi and DFG; none resulted in a conflict of interest. Alexander Stahmann has no personal financial interests to disclose, other than being the leader of the German MS Registry, which receives funding from a range of public and corporate sponsors, recently including G-BA, The German MS Trust, German MS Society, Biogen, Bristol Myers Squibb, Merck, Novartis, Roche and Sanofi; none resulted in a conflict of interest. Rod Middleton has no personal pecuniary interests to disclose, other than being the lead of the UK MS Register which is funded by the MS Society, travel research and conference costs are also funded by them; none resulted in a conflict of interest., (© 2022 MS Forschungs- und Projektentwicklungs-gGmbH (MS Research and Project Development gGmbH).)

Published
2022
Full Text
View/download PDF

20. Vaccination and immunotherapies in neuroimmunological diseases.

Author

Winkelmann A, Loebermann M, Barnett M, Hartung HP, and Zettl UK

Subjects
Humans, Immunologic Factors, Immunotherapy, Pandemics, SARS-CoV-2, Vaccination, COVID-19 prevention & control, COVID-19 Vaccines
Abstract

Neuroimmunological diseases and their treatment compromise the immune system, thereby increasing the risk of infections and serious illness. Consequently, vaccinations to protect against infections are an important part of the clinical management of these diseases. However, the wide variety of immunotherapies that are currently used to treat neuroimmunological disease - particularly multiple sclerosis and neuromyelitis optica spectrum disorders - can also impair immunological responses to vaccinations. In this Review, we discuss what is known about the effects of various immunotherapies on immunological responses to vaccines and what these effects mean for the safe and effective use of vaccines in patients with a neuroimmunological disease. The success of vaccination in patients receiving immunotherapy largely depends on the specific mode of action of the immunotherapy. To minimize the risk of infection when using immunotherapy, assessment of immune status and exclusion of underlying chronic infections before initiation of therapy are essential. Selection of the required vaccinations and leaving appropriate time intervals between vaccination and administration of immunotherapy can help to safeguard patients. We also discuss the rapidly evolving knowledge of how immunotherapies affect responses to SARS-CoV-2 vaccines and how these effects should influence the management of patients on these therapies during the COVID-19 pandemic., (© 2022. Springer Nature Limited.)

Published
2022
Full Text
View/download PDF

21. Tick-borne encephalitis vaccination in multiple sclerosis: A prospective, multicenter study.

Author

Winkelmann A, Metze C, Frimmel S, Reisinger EC, Zettl UK, and Loebermann M

Subjects
Adult, Female, Humans, Male, Middle Aged, Prospective Studies, Treatment Outcome, Vaccination, Viral Vaccines adverse effects, Antibodies, Viral blood, Encephalitis Viruses, Tick-Borne immunology, Encephalitis, Tick-Borne prevention & control, Multiple Sclerosis blood, Multiple Sclerosis drug therapy, Multiple Sclerosis immunology, Neurotransmitter Agents administration & dosage, Viral Vaccines administration & dosage
Abstract

Objective: To assess the changes in disease activity after tick-borne encephalitis (TBE) vaccination in patients with multiple sclerosis (MS) on a variety of disease-modifying drugs and to assess the immunogenicity, safety, and clinical tolerability of the vaccine in this patient group., Methods: We conducted a prospective, multicenter, nonrandomized observational study. We enrolled 20 patients with MS receiving TBE vaccination who had been on disease-modifying treatment (DMT) for at least 6 months. Serum samples were obtained before and after 4 weeks of vaccination to determine the specific TBE antibody response. MS disease activity (Expanded Disability Status Scale and relapse rates) was evaluated for 1 year after immunization. Local and systemic adverse events were registered., Results: In 20 subjects with TBE vaccination, the annualized relapse rate decreased from 0.65 in the year before vaccination to 0.21 in the following year. Expanded Disability Status Scale remained stable during the 2-year period before vaccination and 1 year after vaccination (range: 1.50-1.97). The geometric mean titer (GMT) increased from 169 Vienna units per milliliter (VIEU/mL) to 719 VIEU/mL 4 weeks after vaccination ( p = 0.001), and 77.8% had protective antibody titers after vaccination. In 9 patients treated with beta interferons, GMT increased from 181 VIEU/mL to 690 VIEU/mL ( p = 0.018). Three subjects treated with glatiramer acetate developed a 2- to 9.6-fold increase. Patients treated with fingolimod developed the lowest increase in antibody titer., Conclusion: TBE vaccination showed good tolerability and was safe in patients with MS. MS disease activity was not increased, and annualized relapse rates decreased after vaccination. Vaccine response differs according to the underlying DMT., Trial Registration: ClinicalTrials.gov, clinicaltrials.gov, Identifier: NCT02275741., (Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)

Published
2020
Full Text
View/download PDF

22. Vaccination in Multiple Sclerosis: Friend or Foe?

Author

Zrzavy T, Kollaritsch H, Rommer PS, Boxberger N, Loebermann M, Wimmer I, Winkelmann A, and Zettl UK

Subjects
Humans, Multiple Sclerosis immunology, Vaccination adverse effects, Vaccination methods, Vaccines adverse effects, Vaccines immunology
Abstract

Multiple sclerosis (MS) is a debilitating disease of the central nervous systems (CNS). Disease-modifying treatments (including immunosuppressive treatments) have shown positive effects on the disease course, but are associated with systemic consequences on the immune system and may increase the risk of infections and alter vaccine efficiency. Therefore, vaccination of MS patients is of major interest. Over the last years, vaccine hesitancy has steadily grown especially in Western countries, partly due to fear of sequelae arising from vaccination, especially neurological disorders. The interaction of vaccination and MS has been discussed for decades. In this review, we highlight the immunology of vaccination, provide a review of literature and discuss the clinical consideration of MS, vaccination and immunosuppression. In conclusion, there is consensus that MS cannot be caused by vaccines, neither by inactivated nor by live vaccines. However, particular attention should be paid to two aspects: First, in immunocompromised patients, live vaccines may lead to a stronger immune reaction with signs of the disease against which the patients have been vaccinated, albeit in weakened form. Second, protection provided by vaccination should be controlled in patients who have been vaccinated while receiving immunomodulatory or immunosuppressive treatment. In conclusion, there is evidence that systemic infections can worsen MS, thus vaccination will lower the risk of relapses by reducing the risk of infections. Therefore, vaccination should be in general recommended to MS patients.

Published
2019
Full Text
View/download PDF

23. Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies.

Author

Metze C, Winkelmann A, Loebermann M, Hecker M, Schweiger B, Reisinger EC, and Zettl UK

Subjects
Adolescent, Adult, Aged, Cohort Studies, Female, Fingolimod Hydrochloride adverse effects, Fingolimod Hydrochloride therapeutic use, Humans, Influenza A Virus, H1N1 Subtype immunology, Influenza A Virus, H3N2 Subtype immunology, Influenza B virus immunology, Influenza Vaccines administration & dosage, Male, Middle Aged, Natalizumab adverse effects, Natalizumab therapeutic use, Prospective Studies, Young Adult, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Influenza Vaccines immunology, Multiple Sclerosis drug therapy, Multiple Sclerosis immunology
Abstract

Aims: To evaluate the immunogenicity and safety of a seasonal influenza vaccine in a cohort of multiple sclerosis (MS) patients receiving different immunomodulating/immunosuppressive therapies and assess predictors of immune response., Methods: A prospective, multicenter, non-randomized observational study including 108 patients receiving a trivalent seasonal influenza vaccination was conducted. Influenza-specific antibody titers (H1N1, H3N2, and influenza B) were measured to evaluate rates of seroprotection and seroconversion/significant titer increase. Univariable and multivariable analyses were performed to identify prognostic factors of vaccination outcomes., Results: Regarding the whole cohort, seroprotection rates >70% were achieved for each influenza strain. Interferon-treated patients reached high seroprotection rates (>84%). Good seroprotection rates were seen in patients treated with glatiramer acetate. In particular for H3N2, response rates were low in natalizumab-treated patients and in the small subgroup of fingolimod-treated patients. Patients with a previous disease-modifying therapy and a longer disease duration were less likely to respond sufficiently. No severe adverse events were reported. MS disease activity was not increased after a one-year follow-up period., Conclusion: Vaccination led to good immunogenicity, especially in MS patients treated with interferons and glatiramer acetate. At least for the H1N1 strain, rates of seroprotection and seroconversion/significant titer increase were high (>70% and >60%, respectively) for all therapeutic subgroups. Patients with a longer duration of the disease are exposed to an increased risk of insufficient immune response to vaccination., (© 2018 John Wiley & Sons Ltd.)

Published
2019
Full Text
View/download PDF

24. Host Defense Versus Immunosuppression: Unisexual Infection With Male or Female Schistosoma mansoni Differentially Impacts the Immune Response Against Invading Cercariae.

Author

Sombetzki M, Koslowski N, Rabes A, Seneberg S, Winkelmann F, Fritzsche C, Loebermann M, and Reisinger EC

Subjects
Animals, Antibodies, Helminth immunology, Biomphalaria parasitology, Cytokines immunology, Cytokines metabolism, Disease Models, Animal, Female, Humans, Immune Tolerance immunology, Liver immunology, Liver parasitology, Male, Mice, Protozoan Vaccines immunology, Schistosomiasis mansoni parasitology, Schistosomiasis mansoni prevention & control, Sex Factors, Cercaria immunology, Host-Parasite Interactions immunology, Protozoan Vaccines therapeutic use, Schistosoma mansoni immunology, Schistosomiasis mansoni immunology
Abstract

Infection with the intravascular diecious trematode Schistosoma spp . remains a serious tropical disease and public health problem in the developing world, affecting over 258 million people worldwide. During chronic Schistosoma mansoni infection, complex immune responses to tissue-entrapped parasite eggs provoke granulomatous inflammation which leads to serious damage of the liver and intestine. The suppression of protective host immune mechanisms by helminths promotes parasite survival and benefits the host by reducing tissue damage. However, immune-suppressive cytokines may reduce vaccine-induced immune responses. By combining a single-sex infection system with a murine air pouch model, we were able to demonstrate that male and female schistosomes play opposing roles in modulating the host's immune response. Female schistosomes suppress early innate immune responses to invading cercariae in the skin and upregulate anergy-associated genes. In contrast, male schistosomes trigger strong innate immune reactions which lead to a reduction in worm and egg burden in the liver. Our data suggest that the female worm is a neglected player in the dampening of the host's immune defense system and is therefore a promising target for new immune modulatory therapies.

Published
2018
Full Text
View/download PDF

25. Single-sex infection with female Schistosoma mansoni cercariae mitigates hepatic fibrosis after secondary infection.

Author

Koslowski N, Sombetzki M, Loebermann M, Engelmann R, Grabow N, Österreicher CH, Trauner M, Mueller-Hilke B, and Reisinger EC

Subjects
Animals, Female, Liver pathology, Liver Cirrhosis prevention & control, Male, Mice, Schistosomiasis mansoni immunology, Spleen pathology, Liver Cirrhosis parasitology, Liver Cirrhosis pathology, Schistosoma mansoni isolation & purification, Schistosomiasis mansoni parasitology, Schistosomiasis mansoni pathology
Abstract

Background: Infection with Schistosoma spp. affects more than 258 million people worldwide. Current treatment strategies are mainly based on the anthelmintic Praziquantel, which is effective against adult worms but neither prevents re-infection nor cures severe liver damage. The best long-term strategy to control schistosomiasis may be to develop an immunization. Therefore, we designed a two-step Schistosoma mansoni infection model to study the immune-stimulating effect of a primary infection with either male or female cercariae, measured on the basis of TH1/TH2-response, granuloma size and hepatic fibrosis after a secondary bisexual S. mansoni challenge., Methodology/principle Findings: As a first step, mice were infected with exclusively female, exclusively male, or a mixture of male and female S. mansoni cercariae. 11 weeks later they were secondarily infected with male and female S. mansoni cercariae. At week 19, infection burden, granuloma size, collagen deposition, serum cytokine profiles and the expression of inflammatory genes were analyzed. Mice initially infected with female S. mansoni cercariae displayed smaller hepatic granulomas, livers and spleens, less hepatic fibrosis and higher expression of Ctla4. In contrast, a prior infection with male or male and female S. mansoni did not mitigate disease progression after a bisexual challenge., Conclusions/significance: Our findings provide evidence that an immunization against S. mansoni is achievable by exploiting gender-specific differences between schistosomes.

Published
2017
Full Text
View/download PDF

26. Disease-modifying therapies and infectious risks in multiple sclerosis.

Author

Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, and Zettl UK

Subjects
Animals, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized therapeutic use, Communicable Diseases diagnosis, Fingolimod Hydrochloride adverse effects, Fingolimod Hydrochloride therapeutic use, Humans, Immunosuppressive Agents therapeutic use, Multiple Sclerosis complications, Multiple Sclerosis diagnosis, Risk Factors, Communicable Diseases chemically induced, Communicable Diseases therapy, Immunosuppressive Agents adverse effects, Multiple Sclerosis drug therapy
Abstract

Immunomodulatory and immunosuppressive treatments for multiple sclerosis (MS) are associated with an increased risk of infection, which makes treatment of this condition challenging in daily clinical practice. Use of the expanding range of available drugs to treat MS requires extensive knowledge of treatment-associated infections, risk-minimizing strategies and approaches to monitoring and treatment of such adverse events. An interdisciplinary approach to evaluate the infectious events associated with available MS treatments has become increasingly relevant. In addition, individual stratification of treatment-related infectious risks is necessary when choosing therapies for patients with MS, as well as during and after therapy. Determination of the individual risk of infection following serial administration of different immunotherapies is also crucial. Here, we review the modes of action of the available MS drugs, and relate this information to the current knowledge of drug-specific infectious risks and risk-minimizing strategies.

Published
2016
Full Text
View/download PDF

27. Biosensor for Hepatocellular Injury Corresponds to Experimental Scoring of Hepatosplenic Schistosomiasis in Mice.

Author

Sombetzki M, Koslowski N, Doss S, Loebermann M, Trauner M, Reisinger EC, and Sauer M

Subjects
Alanine Transaminase blood, Alkaline Phosphatase blood, Animals, Anti-Infective Agents chemistry, Aspartate Aminotransferases blood, Bilirubin blood, Disease Models, Animal, Female, Fibrosis physiopathology, Hep G2 Cells, Hepatocytes pathology, Humans, Inflammation, Liver pathology, Liver Diseases blood, Liver Diseases pathology, Mice, Schistosoma mansoni, Schistosomiasis blood, Snails, Biosensing Techniques methods, Liver parasitology, Liver Diseases parasitology, Schistosomiasis parasitology
Abstract

Severe hepatosplenic injury of mansonian schistosomiasis is caused by Th2 mediated granulomatous response against parasite eggs entrapped within the periportal tissue. Subsequent fibrotic scarring and deformation/sclerosing of intrahepatic portal veins lead to portal hypertension, ascites, and oesophageal varices. The murine model of Schistosoma mansoni (S. mansoni) infection is suitable to establish the severe hepatosplenic injury of disease within a reasonable time scale for the development of novel antifibrotic or anti-infective strategies against S. mansoni infection. The drawback of the murine model is that the material prepared for complex analysis of egg burden, granuloma size, hepatic inflammation, and fibrosis is limited due to small amounts of liver tissue and blood samples. The objective of our study was the implementation of a macroscopic scoring system for mice livers to determine infection-related organ alterations of S. mansoni infection. In addition, an in vitro biosensor system based on the detection of hepatocellular injury in HepG2/C3A cells following incubation with serum of moderately (50 S. mansoni cercariae) and heavily (100 S. mansoni cercariae) infected mice affirmed the value of our scoring system. Therefore, our score represents a valuable tool in experimental schistosomiasis to assess severity of hepatosplenic schistosomiasis and reduce animal numbers by saving precious tissue samples.

Published
2016
Full Text
View/download PDF

28. Tick-borne encephalitis virus habitats in North East Germany: reemergence of TBEV in ticks after 15 years of inactivity.

Author

Frimmel S, Krienke A, Riebold D, Loebermann M, Littmann M, Fiedler K, Klaus C, Süss J, and Reisinger EC

Subjects
Animals, Geography, Germany, Humans, Mice, Phylogeny, Time Factors, Ecosystem, Encephalitis Viruses, Tick-Borne physiology, Ixodidae virology
Abstract

The incidence of tick-borne encephalitis has risen in Europe since 1990 and the tick-borne encephalitis virus (TBEV) has been documented to be spreading into regions where it was not previously endemic. In Mecklenburg-West Pomerania, a federal state in Northern Germany, TBEV was not detectable in over 16,000 collected ticks between 1992 and 2004. Until 2004, the last human case of TBE in the region was reported in 1985. Following the occurrence of three autochthonous human cases of TBE after 2004, however, we collected ticks from the areas in which the infections were contracted. To increase the chance of detecting TBEV-RNA, some of the ticks were fed on mice. Using nested RT-PCR, we were able to confirm the presence of TBEV in ticks for the first time after 15 years. A phylogenetic analysis revealed a close relationship between the sequences we obtained and a TBEV sequence from Mecklenburg-East Pomerania published in 1992 and pointed to the reemergence of a natural focus of TBEV after years of low activity. Our results imply that natural foci of TBEV may either persist at low levels of activity for years or reemerge through the agency of migrating birds.

Published
2014
Full Text
View/download PDF

29. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.

Author

Loebermann M, Voss U, Meyer S, Bosse D, Fritzsche C, Klammt S, Frimmel S, Riebold D, and Reisinger EC

Subjects
Adolescent, Adult, Aged, Female, Hemagglutination Inhibition Tests, Hemagglutinins, Viral immunology, Humans, Influenza Vaccines administration & dosage, Influenza, Human blood, Influenza, Human immunology, Male, Middle Aged, Seasons, Vaccines, Subunit, Antibodies, Viral blood, Influenza A Virus, H1N1 Subtype immunology, Influenza A Virus, H3N2 Subtype immunology, Influenza B virus immunology, Influenza Vaccines immunology, Influenza, Human prevention & control, Vaccination methods
Abstract

Unlabelled: Vaccination against influenza is an important means of reducing morbidity and mortality in subjects at risk. The prevalent viral strains responsible for seasonal epidemics usually change annually, but the WHO recommendations for the 2011/2012-season in the Northern hemisphere included the same antigens as for the previous season. We conducted a single-center, single-arm study involving 62 younger (18-60 years) and 64 older (>60 years) adults to test the immunogenicity, safety and tolerability of a trivalent surface antigen, inactivated influenza vaccine produced in mammalian cell-culture. The vaccine contained 15 µg hemagglutinin of each of the virus strains recommended for the 2011-2012 Northern hemisphere winter season (A/California/7/09 (H1N1)-; A/Perth/16/09 (H3N2)-; B/Brisbane/60/08-like strain) in a non-adjuvanted preservative-free formulation. Antibody response was measured by hemagglutination inhibition 21 days after immunization. Adverse events and safety were assessed using subject diary cards and telephone interviews. Seroconversion or a 4-fold antibody increase in antibody titers was detectable against A(H1N1) in 68% of both younger and older adults, against A(H3N2) in 53% and 27%, and against the B influenza strain in 35% and 17%. Antibody titers of 40 or more were observed against A(H1N1) in 87% and 90% of younger and older adults, against A(H3N2) in 98% and 98%, and against the B influenza strain in 93% and 90%. Pre-vaccination antibody titers were protective against A(H1N1), A(H3N2) and B in 38%, 58% and 58%, respectively, of younger and in 43%, 88% and 70% of older adults. Among subjects with previous A(H1N1) vaccination only 48% of younger and 47% of older adults had protective A(H1N1) antibodies at inclusion. Adverse reactions were generally mild. The most frequently reported reactions were pain at the injection site, myalgia and fatigue. The vaccine generated protective antibodies against all three viral strains and had an acceptable safety profile in both younger and older adults., Trial Registration: ClinicalTrials.govNCT01422512.

Published
2013
Full Text
View/download PDF

30. Vaccination against infection in patients with multiple sclerosis.

Author

Loebermann M, Winkelmann A, Hartung HP, Hengel H, Reisinger EC, and Zettl UK

Subjects
Bacterial Infections etiology, Bacterial Infections prevention & control, Disease Progression, Humans, Virus Diseases etiology, Virus Diseases prevention & control, Multiple Sclerosis etiology, Multiple Sclerosis immunology, Vaccination adverse effects
Abstract

Bacterial and viral infections have been shown to induce relapses and accelerate the progression of multiple sclerosis (MS). Vaccination to prevent communicable disease in such patients is, therefore, of key importance. Reports of potentially detrimental effects of immunization on the course of MS, however, have prompted patients and physicians to adopt a cautious attitude towards the use of vaccines. The risks associated with a number of vaccines have been investigated in patients with MS. Vaccines against some diseases, such as tetanus and hepatitis B, are not associated with an elevated risk of MS exacerbation, whereas vaccines against other diseases, such as yellow fever, are contraindicated in patients with MS. Many patients with MS receive immunosuppressive or immunomodulatory therapy, which could make them more susceptible to infectious diseases and might also affect their ability to respond to immunization. Here, we review the indications for and possible adverse effects of vaccines in patients with MS, and address issues of vaccination in the context of immunomodulatory therapy for MS.

Published
2012
Full Text
View/download PDF

31. Bilateral upper arm swelling and weight loss.

Author

Fritzsche C, Loebermann M, and Reisinger EC

Subjects
Adenocarcinoma physiopathology, Aged, Esophageal Neoplasms physiopathology, Gastrostomy, Humans, Male, Palliative Care, Skin Neoplasms physiopathology, Adenocarcinoma secondary, Arm physiopathology, Esophageal Neoplasms pathology, Skin Neoplasms secondary, Weight Loss physiology
Published
2011
Full Text
View/download PDF

32. Confocal laser scanning microscopy for detection of Schistosoma mansoni eggs in the gut of mice.

Author

Holtfreter MC, Stachs O, Reichard M, Loebermann M, Guthoff RF, and Reisinger EC

Subjects
Animals, Female, Mice, Colon parasitology, Microscopy, Confocal methods, Ovum, Schistosoma mansoni cytology
Abstract

Background: The gold standard for diagnosing Schistosoma mansoni infections is the detection of eggs from stool or biopsy specimens. The viability of collected eggs can be tested by the miracidium hatching procedure. Direct detection methods are often limited in patients with light or early infections, whereas serological tests and PCR methods fail to differentiate between an inactive and persistent infection and between schistosomal species. Recently, confocal laser scanning microscopy (CLSM) has been introduced as a diagnostic tool in several fields of medicine. In this study we evaluated CLSM for the detection of viable eggs of S. mansoni directly within the gut of infected mice., Methodology/principal Findings: The confocal laser scanning microscope used in this study is based on the Heidelberg Retina Tomograph II scanning laser system in combination with the Rostock Cornea Module (image modality 1) or a rigid endoscope (image modality 2). Colon sections of five infected mice were examined with image modalities 1 and 2 for schistosomal eggs. Afterwards a biopsy specimen was taken from each colon section and examined by bright-field microscopy. Visualised eggs were counted and classified in terms of viability status., Conclusions/significance: We were able to show that CLSM visualises eggs directly within the gut and permits discrimination of schistosomal species and determination of egg viability. Thus, CLSM may be a suitable non-invasive tool for the diagnosis of schistosomiasis in humans.

Published
2011
Full Text
View/download PDF

33. Borrelia burgdorferi and Anaplasma phagocytophilum coinfection.

Author

Loebermann M, Fingerle V, Lademann M, Fritzsche C, and Reisinger EC

Subjects
Antibodies, Bacterial blood, Ehrlichiosis diagnosis, Female, Germany, Humans, Immunoglobulin G blood, Immunoglobulin M blood, Lyme Disease diagnosis, Middle Aged, Anaplasma phagocytophilum immunology, Borrelia burgdorferi Group immunology, Ehrlichiosis complications, Lyme Disease complications
Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results